Triangle Securities Wealth Management Purchases 441 Shares of Johnson & Johnson (NYSE:JNJ)

Triangle Securities Wealth Management boosted its position in Johnson & Johnson (NYSE:JNJ) by 2.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,756 shares of the company’s stock after buying an additional 441 shares during the quarter. Johnson & Johnson makes up about 1.2% of Triangle Securities Wealth Management’s portfolio, making the stock its 16th biggest position. Triangle Securities Wealth Management’s holdings in Johnson & Johnson were worth $3,411,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Saratoga Research & Investment Management boosted its stake in shares of Johnson & Johnson by 10.7% during the 1st quarter. Saratoga Research & Investment Management now owns 384,564 shares of the company’s stock worth $63,203,000 after buying an additional 37,192 shares during the last quarter. Stack Financial Management Inc raised its holdings in Johnson & Johnson by 2.0% during the first quarter. Stack Financial Management Inc now owns 97,572 shares of the company’s stock worth $16,036,000 after acquiring an additional 1,871 shares in the last quarter. Ipswich Investment Management Co. Inc. boosted its position in Johnson & Johnson by 2.2% during the first quarter. Ipswich Investment Management Co. Inc. now owns 52,113 shares of the company’s stock valued at $8,565,000 after purchasing an additional 1,101 shares during the last quarter. Novak Financial Planning LLC grew its stake in Johnson & Johnson by 4.6% in the first quarter. Novak Financial Planning LLC now owns 1,429 shares of the company’s stock valued at $235,000 after purchasing an additional 63 shares in the last quarter. Finally, Wiley BROS. Aintree Capital LLC raised its stake in shares of Johnson & Johnson by 9.7% during the 1st quarter. Wiley BROS. Aintree Capital LLC now owns 6,285 shares of the company’s stock worth $1,033,000 after purchasing an additional 557 shares in the last quarter. Hedge funds and other institutional investors own 67.25% of the company’s stock.

A number of brokerages recently weighed in on JNJ. SVB Leerink boosted their target price on shares of Johnson & Johnson from $180.00 to $200.00 and gave the stock an “outperform” rating in a report on Wednesday, January 27th. Cowen upped their target price on shares of Johnson & Johnson from $170.00 to $195.00 and gave the company an “outperform” rating in a report on Wednesday, January 27th. JPMorgan Chase & Co. lifted their price target on Johnson & Johnson from $157.00 to $175.00 and gave the stock a “neutral” rating in a report on Wednesday, January 27th. Wells Fargo & Company upped their price objective on Johnson & Johnson from $175.00 to $190.00 and gave the company an “overweight” rating in a research note on Wednesday, January 27th. Finally, Credit Suisse Group lifted their target price on Johnson & Johnson from $168.00 to $193.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $178.60.

Johnson & Johnson stock traded up $0.62 during midday trading on Monday, hitting $161.87. The company’s stock had a trading volume of 46,055 shares, compared to its average volume of 8,015,022. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24. The company has a market cap of $426.16 billion, a price-to-earnings ratio of 25.35, a PEG ratio of 3.06 and a beta of 0.70. Johnson & Johnson has a 1-year low of $133.65 and a 1-year high of $173.65. The company has a 50-day moving average price of $160.97 and a two-hundred day moving average price of $154.54.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Monday, January 25th. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.82 by $0.04. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The company had revenue of $22.50 million during the quarter, compared to the consensus estimate of $21.62 billion. During the same period in the previous year, the business earned $1.88 earnings per share. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. Sell-side analysts forecast that Johnson & Johnson will post 7.99 EPS for the current year.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Article: Basic Economics

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.